4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is used in the design and preparation of ruxolitinib-vorinostat conjugate derivatives which have dual inhibitory activity against Janus kinase (JAK) and histone deacetylase (HDAC).
4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is used in the design and preparation of ruxolitinib-vorinostat conjugate derivatives which have dual inhibitory activity against Janus kinase (JAK) and histone deacetylase (HDAC).